BDTX Company Profile and Key Details
Black Diamond Therapeutics, Inc.
BDTX Stock Price Chart
Stock Price Today
Black Diamond Therapeutics, Inc. (BDTX) stock declined over -1.48%, trading at $2.50 on NASDAQ, down from the previous close of $2.54. The stock opened at $2.55, fluctuating between $2.48 and $2.56 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
Cambridge, MA 02142
United States
Website: https://www.blackdiamondtherapeutics.comContact: 617 252 0848About Company
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 54 |
| Beta | 2.52 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) stock price is $2.50 in the last trading session. During the trading session, BDTX stock reached the peak price of $2.56 while $2.48 was the lowest point it dropped to. The percentage change in BDTX stock occurred in the recent session was -1.48% while the dollar amount for the price change in BDTX stock was -$0.04.
The NASDAQ listed BDTX is part of Biotechnology industry that operates in the broader Healthcare sector. Black Diamond Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Christopher D. Roberts Ph.D.
Advisor
Dr. Elizabeth Buck Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Brent Hatzis-Schoch Esq., J.D.
Chief Operating Officer & Gen. Counsel
Ms. Melanie Morrison
Chief Devel. Officer
Mr. Tai-An Lin Ph.D.
Senior Vice President of Translational Science & Discovery Biology
Dr. Sergey Yurasov M.D., Ph.D.
Chief Medical Officer
Dr. Fang Ni Pharm.D.
Chief Financial Officer, Principal Financial Officer and Chief Bus. Officer
Ms. Elizabeth L. Montgomery
Chief People Officer
Dr. David M. Epstein Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Ms. Erika Jones
Vice President of Fin., Corporation Controller & Principal Accounting Officer
BDTX's closing price is 32.98% higher than its 52-week low of $1.91 where as its distance from 52-week high of $7.66 is -66.84%.
Number of BDTX employees currently stands at 54.
Official Website of BDTX is: https://www.blackdiamondtherapeutics.com
BDTX could be contacted at phone 617 252 0848 and can also be accessed through its website. BDTX operates from One Main Street, Cambridge, MA 02142, United States.
BDTX stock volume for the day was 103.77K shares. The average number of BDTX shares traded daily for last 3 months was 777.92K.
The market value of BDTX currently stands at $141.60M with its latest stock price at $2.50 and 56.59M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com